Valiant Laboratories Ltd. (IN:VALIANTLAB)
:VALIANTLAB
Want to see IN:VALIANTLAB full AI Analyst Report?
VALIANTLAB Stock Chart & Stats
₹73.50
-₹2.57(-2.33%)
At close: 4:00 PM EST
₹73.50
-₹2.57(-2.33%)
Day’s Range― - ―
52-Week Range₹47.60 - ₹114.72
Previous CloseN/A
Volume41.92K
Average Volume (3M)1.58K
Market Cap
₹4.44B
Enterprise Value₹4.94B
Total Cash (Recent Filing)₹629.06M
Total Debt (Recent Filing)₹537.68M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding54,312,500
10 Day Avg. Volume2,243
30 Day Avg. Volume1,577
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.46
Price to Sales (P/S)2.47
P/FCF Ratio-3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B API Manufacturing Business ModelSelling active pharmaceutical ingredients to drug formulators creates recurring, contract- and volume-driven B2B revenue. This model ties the company to long-term manufacturing demand, benefits from repeat orders and customer relationships, and supports predictable industrial revenue over months.
Stable Equity Ratio And Asset BaseA stable equity ratio and relatively steady asset base provide a structural buffer for manufacturing operations. These attributes support operational continuity, provide collateral for financing, and reduce the likelihood of abrupt capital-structure stress in the medium term.
Operates In Specialty & Generic Drug ManufacturingBeing in specialty and generic drug manufacturing links the company to structurally resilient end-markets where demand for ingredients is relatively inelastic. This industry positioning tends to produce steadier order flows and long-term demand visibility for API suppliers.
Bears Say
Negative Free Cash Flow And Poor ConversionSustained negative free cash flow and very weak cash conversion limit the company’s ability to fund capex, repay debt, or invest in growth from operations. This heightens reliance on external financing and raises liquidity and refinancing risk over the coming months.
Declining Margins And Negative Net ProfitEroding gross and operating margins with a negative net result signal structural profit pressure from costs or product mix shifts. Persisting margin weakness undermines internal funding capacity, constrains pricing flexibility, and weakens long-term competitiveness.
Rising Leverage And Negative ROEHigher debt levels alongside a negative ROE increase financial vulnerability: interest obligations rise while returns to shareholders decline. This combination reduces strategic flexibility, increases covenant and refinancing risk, and limits capacity to invest in growth.
Valiant Laboratories Ltd. News
VALIANTLAB FAQ
What was Valiant Laboratories Ltd.’s price range in the past 12 months?
Valiant Laboratories Ltd. lowest stock price was ₹47.60 and its highest was ₹114.72 in the past 12 months.
What is Valiant Laboratories Ltd.’s market cap?
Valiant Laboratories Ltd.’s market cap is ₹4.44B.
When is Valiant Laboratories Ltd.’s upcoming earnings report date?
Valiant Laboratories Ltd.’s upcoming earnings report date is May 19, 2026 which is in 18 days.
How were Valiant Laboratories Ltd.’s earnings last quarter?
Valiant Laboratories Ltd. released its earnings results on Feb 11, 2026. The company reported -₹1.299 earnings per share for the quarter, missing the consensus estimate of N/A by -₹1.299.
Is Valiant Laboratories Ltd. overvalued?
According to Wall Street analysts Valiant Laboratories Ltd.’s price is currently Overvalued.
Does Valiant Laboratories Ltd. pay dividends?
Valiant Laboratories Ltd. does not currently pay dividends.
What is Valiant Laboratories Ltd.’s EPS estimate?
Valiant Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valiant Laboratories Ltd. have?
Valiant Laboratories Ltd. has 54,312,500 shares outstanding.
What happened to Valiant Laboratories Ltd.’s price movement after its last earnings report?
Valiant Laboratories Ltd. reported an EPS of -₹1.299 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.196%.
Which hedge fund is a major shareholder of Valiant Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:VALIANTLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valiant Laboratories Ltd.
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India. Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP.
Technical Analysis
Alpa Laboratories Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Krebs Biochemicals & Industries Ltd.
―
Lasa Supergenerics Ltd.
―
Vivimed Labs Limited
―